Information
REDWOOD CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx...
Original sourceAI Summary
Pulmonx will release Q4 and full year 2024 results on Feb 19, 2025. Management will host a conference call at 1:30 PM PT to discuss results. Pulmonx is a leader in minimally invasive treatments for COPD. The Zephyr Valve is a standard care option for severe emphysema. The FDA approved the Zephyr Valve as a breakthrough device.
Sentiment Rationale
Upcoming earnings report could demonstrate strong revenue growth. Past earnings reports have positively influenced LUNG's stock.
Trading Thesis
Earnings release effects will be immediate. Historical trends show earnings announcements impact stock prices significantly in the short term.
Market-Moving
- Pulmonx will release Q4 and full year 2024 results on Feb 19, 2025.
- Management will host a conference call at 1:30 PM PT to discuss results.
- Pulmonx is a leader in minimally invasive treatments for COPD.
Key Facts
- Pulmonx will release Q4 and full year 2024 results on Feb 19, 2025.
- Management will host a conference call at 1:30 PM PT to discuss results.
- Pulmonx is a leader in minimally invasive treatments for COPD.
- The Zephyr Valve is a standard care option for severe emphysema.
- The FDA approved the Zephyr Valve as a breakthrough device.
Companies Mentioned
- COPD (COPD)
- ZSAN (ZSAN)
- AVGR (AVGR)
Earnings
Earnings reports typically influence stock prices significantly, and Pulmonx's strong product position may drive investor interest.